FDA Approves Moderna’s mNEXSPIKE COVID-19 Vaccine After Phase III Trial Shows Comparable Efficacy to Spikevax

Publication date: Jun 22, 2025

The findings indicate that mNEXSPIKE meets the required standards for efficacy established by regulatory authorities. This approval marks another development in Modernas efforts to expand its portfolio of vaccines targeting COVID-19. Newsflash | Powered by GeneOnline AISource: GO-AI-ne1Date: June 2, 2025Author Mark Chiang

Concepts Keywords
2025author Approves
Covid Chiang
June Comparable
Moderna Covid
Vaccine Efficacy
Fda
Iii
Mark
Mnexspike
Modernas
Phase
Shows
Spikevax
Trial
Vaccine

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease MESH emergency

Original Article

(Visited 5 times, 1 visits today)